NasdaqGS:BBIOBiotechs
A Look At BridgeBio Pharma (BBIO) Valuation As New Acoramidis Phase 3 Data Draws Market Attention
BridgeBio Pharma (BBIO) is in focus after announcing it will share long term efficacy and safety data for acoramidis in ATTR-CM at the American College of Cardiology Annual Scientific Sessions.
See our latest analysis for BridgeBio Pharma.
The latest acoramidis update comes as BridgeBio’s share price sits at US$71.61, with a 1-day share price return of 4.49% and a 30-day share price return of 5.45%. However, a 90-day share price return decline of 6.43% contrasts with a very strong 1-year...